Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction

Circulation Research

Volumn 108, Issue 5, 2011, Pages 582-592

  Arslan, Fatih ^a,b   Smeets, Mirjam B ^a   Riem Vis, Paul W ^a   Karper, Jacco C ^c,d   Quax, Paul H ^c,d   Bongartz, Lennart G ^a   Peters, John H ^e,f   Hoefer, Imo E ^a   Doevendans, Pieter A ^a   Pasterkamp, Gerard ^a   De Kleijn, Dominique P ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Einthoven Laboratory for Experimental Vascular Medicine   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

heart failure; immune system; inflammation; myocardial infarction; remodeling

Indexed keywords

ALPHA4 INTEGRIN; COLLAGEN; ECTODYSPLASIN A; FIBRONECTIN; GELATINASE A; GELATINASE B; TOLL LIKE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; ASCENDING AORTA SURGERY; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR INFLAMMATION; CELL TRANSDIFFERENTIATION; CLINICAL EVALUATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME ACTIVITY; HEART CONTRACTION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PERFORMANCE; HEART VENTRICLE CONTRACTILITY; HYPOHIDROTIC ECTODERMAL DYSPLASIA; LEFT CORONARY ARTERY; MALE; MODULATION; MONOCYTE; MOUSE; MYOFIBROBLAST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CROSS LINKING; SURVIVAL; SYSTOLE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBRONECTINS; HEART; INTEGRIN ALPHA4; LEUKOCYTES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; SURVIVAL; TOLL-LIKE RECEPTOR 2; VENTRICULAR REMODELING;

EID: 79952745548     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.224428     Document Type: Article

References (32)

1. American Heart Association. International Cardiovascular Disease Statistics. Statistical Fact Sheet-Populations. 2009 Update. Dallas, TX: American Heart Association. Available at: http://www.americanheart.org/ downloadable/heart/1236204012112INTL.pdf.
2. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008;58:88-111.
3. McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation. 2004;110: 3281-3288. (Pubitemid 39525078)
4. Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res. 1999;43:838-849. (Pubitemid 29413183)
5. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344-350. (Pubitemid 38944258)
6. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009;119:1386-1397.
7. Zhang P, Cox CJ, Alvarez KM, Cunningham MW. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol. 2009; 183:27-31.
8. Kitahara T, Takeishi Y, Harada M, Niizeki T, Suzuki S, Sasaki T, Ishino M, Bilim O, Nakajima O, Kubota I. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res. 2008;80:40-46.
9. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol. 2007;19:3-10. (Pubitemid 46498750)
10. Schoneveld AH, Hoefer I, Sluijter JP, Laman JD, de Kleijn DP, Pasterkamp G. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis. 2008;197:95-104. (Pubitemid 351273277)
11. Gondokaryono SP, Ushio H, Niyonsaba F, Hara M, Takenaka H, Jayawardana ST, Ikeda S, Okumura K, Ogawa H. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol. 2007;82:657-665. (Pubitemid 47367158)
12. Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De WL. The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem. 2002;277:14467-14474. (Pubitemid 34952511)
13. Manabe R, Oh-e N, Sekiguchi K. Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem. 1999;274:5919-5924. (Pubitemid 29109250)
14. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol. 1998;142:873-881. (Pubitemid 28381502)
15. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ. Origin of cardiac fibroblasts and the role of periostin. Circ Res. 2009; 105:934-947.
16. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544-2565. (Pubitemid 351670463)
17. Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation. 1976; 53(suppl I):I-204 -I-206.
18. Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr Pharm Des. 2008;14:1205-1216. (Pubitemid 351997833)
19. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation. 2010;121:80-90.
20. Schoneveld AH, Oude Nijhuis MM, van MB, Laman JD, de Kleijn DP, Pasterkamp G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res. 2005;66: 162-169. (Pubitemid 40357879)
21. Arslan F, Keogh B, McGuirk P, Parker AE. TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm. 2010;2010:704202.
22. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G, de Kleijn DP. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008;102:257-264. (Pubitemid 351674064)
23. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ, Pohlman TH, Shimpo H, Verrier ED. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114(suppl I): I-270 -I-274.
24. Matzinger P. The danger model: a renewed sense of self. Science. 2002; 296:301-305. (Pubitemid 34303674)
25. Choi MG, Hynes RO. Biosynthesis and processing of fibronectin in NIL. 8 hamster cells. J Biol Chem. 1979;254:12050-12055. (Pubitemid 10143676)
26. Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev. 2007;218:126-134. (Pubitemid 47052306)
27. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, bou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG. CCL2/ monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96:881-889. (Pubitemid 40604972)
28. Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N, Wen J, Egashira K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2003;108: 2134-2140. (Pubitemid 37337591)
29. Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE, Ikeda U. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res. 2006;99:891-899. (Pubitemid 44556389)
30. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87: 1285-1342. (Pubitemid 350041472)
31. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF III. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276:10229-10233.
32. Cantor JM, Ginsberg MH, Rose DM. Integrin-associated proteins as potential therapeutic targets. Immunol Rev. 2008;223:236-251. (Pubitemid 351986185)